Abstract
Aim The aim of our research was an evaluation of possibility to use PRAME gene expression as a marker of minimal residual disease (MRD) in multiple myeloma (MM) patients. Previously we have detected high frequency of PRAME gene expression among patients with advanced stages of MM (68.5%). Material and Methods Two pairs of primers complementary to PRAME exon 5 and 6 were designed. PRAME gene expression was analyzed in bone marrow cells by 2-step reverse-transcription-polymerase chain reaction (RT-PCR). 24 initially PRAME-posistive MM patients were studied on day +100 and one year after high dose therapy with autologous peripheral blood stem cell transplantation (PBSCT). Results On day +100 after PBSCT PRAME expression was found in 22 cases, in 5 patients in the absence of plasma cells in bone marrow. After 1 year among 5 patients with complete clinico-hematological remission PRAME positive cells persisted in 3 cases. Patients who were PRAME-negative on day +100 are still in remission. Conclusion Detection of PRAME gene seems to be used as a molecular marker for definition of MRD. Our results suggest that complete molecular remission after PBSCT may be achieved only in a few MM patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call